在里斯本举行的心脏机器人导航会议上, 导管精度将展示FDA批准的非侵入性3D VIVO技术. Catheter Precision to present FDA-cleared, non-invasive 3D VIVO technology at cardiac robotic navigation meeting in Lisbon.

美国医疗设备公司Catheter Precision将在10月28日至29日在里斯本举行的国际心脏病机器人导航学会会议上介绍其VIVO技术。 Catheter Precision, a U.S. medical device company, will present its VIVO technology at the International Society for Cardiac Robotic Navigation Meeting in Lisbon on October 28-29. VIVO是一个非侵入性三维成像系统,用于在程序之前查明心血管不全,目的是加强工作流程和缩短程序时间。 VIVO is a non-invasive 3D imaging system for identifying ventricular arrhythmias prior to procedures and aims to enhance workflow and reduce procedure time. 这项技术已获得FDA的批准和CE标志. The technology has FDA clearance and a CE mark. 介绍将包括临床数据和欧洲登记处的最新情况。 Presentations will include updates on clinical data and the European Registry.